A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53
- PMID: 21317445
- PMCID: PMC3248136
- DOI: 10.18632/oncotarget.183
A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53
Figures

Comment on
-
A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.Oncotarget. 2010 Oct;1(6):405-422. doi: 10.18632/oncotarget.175. Oncotarget. 2010. PMID: 21311097 Free PMC article.
References
-
- Li FP, Fraumeni JF., Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747–752. - PubMed
-
- Li FP, Fraumeni JF, Jr., Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362. - PubMed
-
- Yeung AT, Patel BB, Li XM, Seeholzer SH, Coudry RA, Cooper HS, Bellacosa A, Boman BM, Zhang T, Litwin S, Ross EA, Conrad P, Crowell JA, Kopelovich L, Knudson A. One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res. 2008;68:7579–7586. - PMC - PubMed
-
- Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243–1252. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous